Program Announcement for the Defense Health Agency

Breast Cancer Research Program

Transformative Breast Cancer Consortium Award

Funding Opportunity Number: HT942526BCRPTBCCA

Pre-Application Due: June 12, 2026

Application Due: September 30, 2026

This program announcement must be read in conjunction with the General Application Instructions, version CD26_01.

Content

Before You Begin

- **Active SAM.gov, eBRAP.org and Grants.gov registrations are required for application submission.** User registration for each of these websites can take several weeks or longer. Each applicant must ensure their registrations are active and up to date prior to application preparation.
- **Read this funding opportunity announcement in the order it is written before beginning to prepare application materials.** It is the responsibility of the applicant to determine whether the proposed research meets the intent of this funding opportunity and that all parties meet eligibility requirements.
- **To support application preparation, additional resources are available** including an application process FAQ, a Guide for Intragovernmental & Intramural Applicants and a CDMRP Video Series detailing the application process.

Who to Contact for Support

eBRAP Help Desk

301-682-5507
help@eBRAP.org

Questions regarding funding opportunity submission requirements, as well as technical assistance related to pre-application or intramural application submission.

Grants.gov Support Center

800-518-4726
International: 1-606-545-5035
support@grants.gov

Questions regarding Grants.gov registration and Workspace.

This document uses internal links; you can go back to where you were by pressing the Alt + left arrow keys (Windows) or command + left arrow keys (Macintosh) on your keyboard.

Click ⓘ to be taken to additional guidance and instructions within the General Application Instructions (GAI).

1. Basic Information About the Funding Opportunity

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Transformative Breast Cancer Consortium Award supports collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applications must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. The consortium's collaborative efforts must make a transformative impact in breast cancer. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges.

Distinctive Features: This funding mechanism allows for up to five Principal Investigators (PIs) which includes the Consortium Director and three or four Project Team PIs. Applications must include at least one breast cancer consumer advocate per project team. Only the Consortium Director will submit a pre-application, but all PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Consortium Director and Project Team PIs) applications by the full application deadline may result in administrative withdrawal.

Funding Details: The Congressionally Directed Medical Research Programs (CDMRP) expects to allot roughly $35 million (M) to fund approximately one Transformative Breast Cancer Consortium Award application with a total cost cap of $35M. The maximum period of performance is four years. It is anticipated that the award made from this FY26 funding opportunity will be funded with FY26 funds, which will expire for use on September 30, 2032. The award supported with FY26 funds will be made no later than September 30, 2027.

Submission and Review Dates and Times

- **Pre-Application (Preproposal) Submission Deadline:** 5:00 p.m. Eastern Time (ET), June 12, 2026
- **Invitation to Submit an Application:** July 16, 2026
- **Application Submission Deadline:** 11:59 p.m. ET, September 30, 2026
- **End of Application Verification Period:** 5:00 p.m. ET, October 5, 2026
- **Peer Review:** December 2026
- **Programmatic Review:** January 2027
- **Invitation for Oral Presentation:** February 2027
- **Programmatic Review, Stage 2:** March 2027

Announcement Type: Initial

Funding Opportunity Number: HT942526BCRPTBCCA

Assistance Listing Number: 12.420

2. Eligibility Information

2.1. Eligible Applicants

2.1.1. Organization

Extramural and intramural U.S. Department of War (DOW) organizations are eligible to apply, ***including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities***.

2.1.2. Principal Investigator

Independent investigators affiliated with an eligible organization are eligible to be named PI, also referred to as the Consortium Director, or Project Team PI on the application, regardless of ethnicity, nationality or citizenship status.

The Consortium Director must commit and maintain a minimum level of time and effort of 25% during the period of performance to direct and manage the consortium ***and*** to lead their own project team.

An investigator may be named as Consortium Director on only one pre-application or full application under this funding opportunity.

There are no limits on the number of pre-applications for which an investigator may apply as a Project Team PI for this funding opportunity.

Investigators named as Consortium Director on a pre-application or full application submitted under funding opportunity HT942526BCRPTBCCDA are not eligible to be named as the Consortium Director on an application submitted under the current funding opportunity.

2.2. Cost Sharing

Cost sharing is not an eligibility requirement.

2.3. Other

Awards are made to eligible ***organizations***, not to individuals. Refer to the GAI for additional recipient qualification requirements.

3. Program Description

The Defense Health Agency Contracting Activity (DHACA) is soliciting applications to this funding opportunity using delegated authority provided by United States Code, Title 10, Section 4001 (10 USC 4001). The CDMRP is the program office managing this FY26 funding opportunity as part of the BCRP. The CDMRP is located within the Defense Health Agency Research and Development (DHA R&D), which is a part of the Department of Defense, DOD, herein referred to using the secondary title Department of War, DOW. Congress initiated the BCRP in FY92 to support innovative, high-impact research, with a mission of ending breast cancer for Service Members and their Families, Veterans, and the general public. Appropriations for the BCRP from FY92 through FY25 totaled $4.52 billion. The FY26 appropriation is $145M.

The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer. Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, and facilitate productive collaborations.

The BCRP brief overview called *The Breast Cancer Landscape* describes what is currently known about the most pertinent topics that are consistent with the BCRP's mission of ending breast cancer. Considering the current breast cancer landscape and the program's mission, the BCRP seeks to invest in research that addresses the following **FY26 BCRP overarching challenges**:

- Prevent breast cancer (primary prevention)
- Identify determinants of breast cancer initiation, risk, or susceptibility
- Distinguish deadly from non-deadly breast cancers
- Conquer the problems of overdiagnosis and overtreatment
- Identify what drives breast cancer growth; determine how to stop it
- Identify why some breast cancers become metastatic
- Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
- Revolutionize treatment regimens by replacing them with ones that do all of the following: improve survival, are more effective, and are less toxic
- Eliminate the mortality associated with metastatic breast cancer

3.1. Intent of the Transformative Breast Cancer Consortium Award

The intent of the FY26 BCRP Transformative Breast Cancer Consortium Award (TBCCA) is to support collaborations and ideas that will transform the lives of individuals with, and/or at risk for, breast cancer and will significantly accelerate progress toward ending breast cancer. Applicants must bring together different perspectives to develop new paradigms that will solve fundamental yet overarching problems in breast cancer. This award requires a team-based approach with a consortium of exceptional researchers and breast cancer consumer advocates, whose collaborative efforts will make a transformative impact in breast cancer. The consortium's intended transformation must occur in people's lives, and not in the health care or research system.

This is a separate award mechanism from the FY26 BCRP Transformative Breast Cancer Consortium Development Award (TBCCDA) which provides successful applicants with the time and resources needed to bring investigators and breast cancer consumer advocates together to establish a consortium framework and conduct preliminary research in support of an application to a future, full BCRP TBCCA (pending availability of funds). For FY26, investigators may be named as Consortium Director on an application submitted to either (but not both) of these award mechanisms. ***It is not necessary to receive a development award in order to apply for the current funding opportunity or anticipated full consortium awards in the future.*** Detailed information on the FY26 BCRP TBCCDA is available under a separate program announcement (HT942526BCRPTBCCDA).

The FY26 BCRP TBCCA supports a consortium composed of at least four, but no more than five, project teams, each investigating different projects under a central hypothesis. No more than two project teams may be based at one institution. The consortium must integrate each team's work so that every component is working toward the consortium's central hypothesis. *Note: The BCRP does not intend this award to replace, supplement, duplicate or compete with other collaborative research efforts, such as the National Cancer Institute (NCI) Specialized Programs of Research Excellence (SPORE), and it should not represent a collection of related Program Project grants or subprojects.*

The consortium must propose work that is innovative. In addition, the FY26 BCRP TBCCA will include funds for "seed projects" to pursue brand-new, high-risk/high-reward concepts that arise from the work during the award period.

The Breast Cancer Landscape describes the reality of breast cancer and identifies overarching challenges to progress the field. ***Research funded under this award mechanism should result in answers that will fundamentally and significantly transform and disrupt the present landscape.***

Although not all-inclusive, applications that propose the following as the primary effort(s) or central hypothesis of the consortium will ***not*** meet the intent of this award mechanism:

- NCI Program Project or SPORE grants or applications.
- Conducting drug screens or testing a "cocktail" of therapeutics.
- Targeting a single gene or protein.
- Developing a new derivative or formulation of an old drug.
- Conducting genomic landscape mapping analyses.
- Seeking to improve existing technologies (e.g., mammography or magnetic resonance imaging screening).

3.1.1. Key Elements for the TBCCA

Applications must include the following:

- Research that includes truly innovative and brand-new, paradigm-shifting work in breast cancer that will address vital issues in a unique way. The research must address one (or more) of the above overarching challenges or, with adequate justification, address a different issue that meets the intent of the award mechanism and addresses the BCRP's mission of ending breast cancer. If the application addresses a different fundamental issue, the application must couple it with at least one of the overarching challenges and provide justification.

- Research that includes different disciplines that come together to address ending breast cancer with an ecologic approach. The consortium's proposed research must look at all aspects of the disease and bring together these different perspectives into one overarching plan for a deep, definitive dive into the overarching challenge(s) or other fundamental issue(s) identified in the application. The plan should also include previously unaddressed or unanswered issues related to the hypothesis.
- A plan that describes in detail the integration across the consortium in all aspects, including administration, logistics, and substance. Applications must describe the substantive integration across and among teams that are necessary for the work. The required communication plan and administrative management plan will not suffice to show integration, nor will identifying individual team members who will cross teams. The application must provide a detailed explanation of the substantive research processes that will be integrated.

The application must propose a synergistic, highly integrated, multidisciplinary and multi-institutional consortium of leading scientists, clinicians, and breast cancer consumer advocates that will address a major problem in a way that a single investigator or group could not accomplish. ***While the project teams are made up of different groups, each with its own PI, the teams must all work on the major problem identified in the application and under the leadership of the Consortium Director.*** Proposed research may include phase 1 clinical trials and collaborations with pharmaceutical or biotechnology industry scientists and/or companies, as appropriate. However, clinical trials are not required, and the primary thrust of the application should not be a clinical trial.

All applications must address the following key features:

1. IMPACT

Demonstrate potential to transform or improve the lives of individuals with, and/or at risk for, breast cancer. The time to the final impact may vary, but the application must demonstrate potential for transformative outcomes that will significantly advance the BCRP's mission of ending breast cancer. The application must provide a clear and compelling explanation of how the effort will be transformative for individuals with, and/or at risk for, breast cancer. Applications proposing research that represents an incremental advance in breast cancer do not meet the intent of this award mechanism.

2. INNOVATION

Pursue innovative, high-risk/high-reward research with the potential to change existing paradigms, or develop new paradigms. Innovative research may introduce a new paradigm, look at existing problems from new perspectives, or exhibit other highly creative qualities. In addition to the requirement that the consortium's overall research be innovative, applications must describe a plan to support the pursuit of innovative concepts through "seed projects," i.e., the development of new concepts that emerge during the course of the award. These "seed projects" should enable the research team to explore new avenues of high-risk/high-reward ideas that were not part of the original application, but that develop during the project and are within the scope of the overall vision of the research. The consortium must reserve a portion of the total direct budget costs (no more than 5%) to support the "seed projects." The consortium may not use these funds for equipment or travel.

3. CONSORTIUM

Integrate project teams consisting of preeminent investigators and consumer advocates from appropriate disciplines and institutions. Applications should include a robust

consortium of researchers with the combined backgrounds and breast cancer-related expertise to enable successful conduct of the proposed research. The application should emphasize integrating the most highly qualified investigators and consumer advocates to focus on the research problem, regardless of their location. These investigators must include highly accomplished scientists, clinicians and promising young investigators in the targeted areas of research who collectively represent the best team to solve the problem(s) identified. The consortium should propose a research effort broad enough to require a multidisciplinary approach that is reflected in the composition of the consortium team. ***The BCRP encourages applications to include scientists from nontraditional disciplines.***

The award mechanism is structured with a Consortium Director and at least three, but no more than four, Project Team PIs representing at least two institutions. ***The Consortium Director is responsible for the day-to-day management of the consortium, as well as for leading their own project team.*** The Consortium Director, together with the Project Team PIs, are jointly responsible for leading and executing the proposed research projects. A central hypothesis must integrate all research projects to result in answers that will fundamentally and significantly transform and disrupt the present breast cancer landscape.

Incorporate breast cancer consumer advocates into every aspect of the proposed consortium's activities. The consortium must include at least one breast cancer consumer advocate per project team. The consumer advocates should represent the perspective of the patient population(s) that are most relevant to the consortium's proposed research. The consumer advocates must have an active role in every aspect of the proposed consortium's work, ***including consortium conception and design***, ongoing discussion, decisions and oversight, program evaluation, and dissemination of information to the public. The consortium must integrate consumer advocates from each project team as active participants in leadership and decision-making committees for the consortium. Examples of appropriate integration include membership on the advisory board(s) and steering committee(s), participation in each project team and attendance at all consortium-related meetings. ***As lay representatives, the consumer advocates must be individuals who have been diagnosed with breast cancer and are actively involved in breast cancer advocacy organization. They must perform their role in the project independently of their employment and cannot be employees of any of the organizations participating in the application. The consumer advocates must have a high level of familiarity and training involving science and current issues in breast cancer research.***

4. INTEGRATION

Provide a plan that describes in detail the integration across the consortium in all aspects, including administration, logistics and substance. Applications must demonstrate the substantive integration across and among teams that are necessary for the work. The integration plan must provide a detailed explanation of the substantive research processes that will be integrated.

5. IMPLEMENTATION

Provide a strategy for implementation. Projects must demonstrate solid scientific rationale, and applications ***must*** include published and/or preliminary data that support the feasibility of their hypotheses and/or approaches. The application must include a detailed research management plan that identifies critical milestones, outlines the innovations and technical solutions to accomplish the milestones, and explains the plan for translation of these solutions to individuals with, and/or at risk for, breast cancer. The proposed plan must present an exceptional level of innovation and creativity.

Accelerate research progress through communication. Communication between and among consortium team members is essential to the success of the consortium. Applications must include a strategy for sharing data in real time and using information technologies to facilitate timely and effective communication and cooperation. The communication plan should specify the processes and tools for utilization in regular and structured communication. The consortium should take full advantage of state-of-the-art communication and data sharing tools in addition to formal and informal meetings. The application must include the framework for the communication plan and identify the individual(s) who will maintain the data sharing and communications technologies.

Provide an effective, coordinated administrative management plan that integrates and optimizes the research and collaborations. The Consortium Director must commit a minimum level of time and effort of 25% to direct and manage an initiative of this magnitude, as well as lead their own project team. The Consortium Director must have the scientific ability and proven administrative ability to oversee large research programs and a proven record of leadership, including experience in the effective use of communication tools and the management of multifaceted and multidisciplinary projects. The administrative management plan must explain the organization and management of the consortium. The plan should specify the processes and tools for utilization in project meeting scheduling, reviews of research findings, ensuring multidisciplinary authorship of all publications arising from the consortium's work, and other issues of common concern to the consortium and its investigators. The administrative management plan also must describe procedures and processes for maximizing the resources (e.g., databases, animal models) and products (e.g., antibodies) generated by the consortium and how the scientific community will gain access to these resources and products. The consortium must reserve a portion of the total direct budget costs for a program manager.

3.1.2. Other Important Considerations for the TBCCA

The FY26 BCRP Transformative Breast Cancer Consortium Award application review requires an ***invited*** oral presentation, as described in Section 4.4.

Award Structure: The FY26 BCRP TBCCA allows for up to five PIs (the Consortium Director and three or four Project Team PIs). ***The Consortium Director is responsible for the majority of the administrative tasks associated with application submission and the day-to-day management of the consortium. In addition, the Consortium Director is responsible for leading their own project team.*** The Consortium Director and Project Team PIs each have different submission requirements; however, all PIs should contribute significantly to the development of the proposed research project, including the Project Narrative, Statement of Work (SOW) and other required components. If recommended for funding, each PI will be named on separate awards to the recipient organization(s). Each award will be subject to separate reporting, regulatory, and administrative requirements. For individual submission requirements for the Consortium Director and Project Team PIs, refer to Section 5.3, Submission Instructions.

In-Progress Reviews: The FY26 BCRP TBCCA requires the Consortium Director, Project Team PIs and consumer advocates to present an update on progress toward accomplishing research milestones and goals of the consortium and each project at an annual In-Progress Review (IPR) Meeting. The intent of the IPR Meeting is to assess research progress, address problems and define future directions. TBCCA awardees must attend annual IPR meetings at the conclusion of year 1 and every subsequent year in the period of performance. Members of the BCRP Programmatic Panel, CDMRP staff, and the DHACA Grants Officer will attend the IPR to facilitate oversight and provide feedback to the consortium. IPR meetings will either be held in

person in the National Capital Area or virtually, at the discretion of the government. Continued funding may be contingent upon the successful completion of specific research milestones and goals.

In addition to IPR meetings, the consortium must hold biannual workshops, at the PIs' institutions or virtually, to facilitate ongoing communication and exchange of information within the consortium, as well as with advisory board(s) and/or steering committee(s).

In accordance with the National Defense Authorization Act for Fiscal Year 2026, Section 732, CDMRP does not support the conduct of painful research (U.S. Department of Agriculture pain category D or E) involving domestic cats or dogs, except for studies relating to military or service animals.

Clinical research including projects involving human data, human anatomical substances, and/or interaction with human subjects **is** permitted. **Clinical trials** ***(e.g., up to and including phase 1 or equivalent)*** **are allowed, but not required, within this funding opportunity.**

All projects should adhere to a core set of standards for rigorous study design and reporting to maximize the reproducibility and translational potential of clinical and preclinical research, such as those described in the STROBE, CONSORT, SPIRIT and ARRIVE 2.0 guidelines.

The proposed research must be relevant to Service Members, Veterans, their Families and/or the American Public. PIs are encouraged to integrate and/or align their research projects with DOW and/or VA research laboratories and programs. Collaboration with the DOW and/or VA is also encouraged. A list of websites that may be useful in identifying additional information about ongoing DOW and VA areas of research interest or potential opportunities for collaboration can be found in Appendix 10 of the GAI.

A congressionally mandated Metastatic Cancer Task Force was formed with the purpose of identifying ways to help accelerate clinical and translational research aimed at extending the lives of advanced state and recurrent patients. As a member of the Metastatic Cancer Task Force, the CDMRP encourages applicants to review the task force recommendations and submit research ideas to address these recommendations, provided they are within the limitations of this funding opportunity and align with the FY26 BCRP priorities.

3.2. Funding Instrument

The funding instrument for awards made under the program announcement will be cooperative agreements (31 USC 6305) based on anticipated "substantial involvement" on the part of CDMRP. Substantial involvement means that, after award, CDMRP staff will assist, guide, coordinate and/or participate in project activities including but not limited to IPR meetings wherein recommendations for continued funding will be made based on overall study progress.

3.3. Funding Details

Period of Performance: The maximum period of performance is **four** years.

Cost Cap: The combined total costs budgeted for the entire period of performance in the applications of the Consortium Director and the Project Team PIs performance should not exceed **$35M**. If indirect cost rates have been negotiated, indirect costs are to be budgeted in accordance with the organization's negotiated rate. Collaborating organizations should budget associated indirect costs in accordance with each organization's negotiated rate.

All direct and indirect costs of any subaward or contract must be included in the direct costs of the primary award.

The applicant may request the entire maximum funding amount for a project that may have a period of performance less than the maximum **four** years.

The appropriateness of the budget for the proposed research will be assessed during peer review.

A separate award will be made to each PI's organization.

Direct Cost Restrictions: For this award mechanism, direct costs:

Must be requested for:

- Costs associated with meetings described in Section 8.3.
- Costs for the PIs and consumer advocates to present project information or disseminate project results at biannual consortium workshops to facilitate ongoing communication and exchange of information within the consortium, as well as with advisory board(s) and/or steering committee(s). The biannual workshops are in addition to IPR meetings described in Section 8.3. The consortium may hold the biannual workshops at the PIs' institutions or virtually. For planning purposes, PIs should assume that they will hold the workshops at one of the PIs' institutions.
- Costs (no more than 5% of the total direct costs) for "seed projects" to support the pursuit of innovative ideas. The PIs should develop "seed projects" during the project and they must align with the scope of the overall vision of the research. Applicants should allocate direct costs for these "seed projects" into the "other direct cost" category of the year 1 budget. The consortium may not use funds for "seed projects" for equipment or travel.

May be requested for (not all-inclusive):

- Consortium-related meetings, teleconferences and travel between/among participating investigators and consumer advocates.
- Costs related to identifying and acquiring research resources.
- Computers and software required to participate in the consortium.
- Other costs associated with planning and developing the consortium collaborations, communications and resources.
- Research subject compensation and reimbursement for study-related out-of-pocket costs (e.g., travel, lodging, parking, costs associated with caregiving, and resources/equipment to enable participation), if applicable.
- Costs for two investigators per project to travel to one scientific/technical meeting per year in addition to the required meetings described in Section 8.3. The intent of travel costs to scientific/technical meetings should be to present project information or disseminate project results from the FY26 BCRP Transformative Breast Cancer Consortium Award.

4. Application Contents and Format

4.1. Application Overview

Application submission is a two-step process requiring both a ***pre-application*** submitted via the Electronic Biomedical Research Application Portal (eBRAP) and a ***full application*** submitted through eBRAP or Grants.gov. Depending on the submission portal, certain aspects of the application will differ.

Intramural DOW organizations submitting a full application should follow instructions for submission through eBRAP.

Extramural organizations submitting a full application must follow instructions for submission through Grants.gov.

4.2. Pre-Application Components

The Initiating PI must submit the following pre-application components.

Upload documents as individual PDF files unless otherwise noted. Files must comply with the formatting guidelines listed in the GAI.

- **Preproposal Narrative (three-page limit):** The Preproposal Narrative page limit applies to text and non-text elements (e.g., figures, tables, graphs, photographs, diagrams, chemical structures, drawings) used to describe the project. Inclusion of URLs that provide additional information to expand the Preproposal Narrative and could confer an unfair competitive advantage is prohibited and may result in administrative withdrawal of the pre-application.

  The Preproposal Narrative should include the following:

  - How will the proposed research fundamentally and significantly transform and disrupt the present breast cancer landscape?
  - How does the consortium bring different disciplines together with one overarching plan to address breast cancer with an ecologic approach?
  - How will the proposed research be innovative and introduce brand-new paradigms in breast cancer?
  - How will the consortium's proposed deep, definitive dive into one (or more) of the overarching challenge(s) or fundamental issue(s) in breast cancer explore or address the challenge or issue in a manner not yet attempted. Explain how and/or why this challenge or issue has not yet been explored using the proposed research.
  - How will the proposed research make a transformative impact on the lives of the individuals with, and/or at risk for, breast cancer? How will the outcomes of the proposed research significantly accelerate progress towards ending breast cancer?
  - What is the overall organization of key personnel, including consumer advocates, and what will each team member's role be in the consortium? How will the consortium team be integrated to address an overarching problem in breast cancer in a way that could not be accomplished by a single investigator or group?
  - How will the consortium be integrated in all aspects, including administration, logistics and substance?

- **Pre-Application Supporting Documentation:** The items to be included as supporting documentation for the pre-application ***must be uploaded as individual files*** and are limited to the following:
    - References Cited (one-page limit): List the references cited (including URLs if available) in the Preproposal Narrative using a standard reference format that includes the full citation (i.e., author[s], year published, reference title, and reference source, including volume, chapter, page numbers, and publisher, as appropriate).
    - List of Abbreviations, Acronyms, and Symbols: Provide a list of abbreviations, acronyms and symbols used in the Preproposal Narrative.
    - Key Personnel Biographical Sketches: All biographical sketches should be uploaded as a single combined file. Biographical sketches should be used to demonstrate background and expertise through education, positions, publications and previous work accomplished.
    - Additional Information: One page for additional information that the PIs can use, at their discretion, to provide supporting data or rationale for the pre-application.

4.3. Full Application Components

Applicants must receive an invitation to submit a full application. Uninvited full application submissions will be rejected.

The CDMRP requires separate full application package submissions for the Consortium Director and each Project Team PI, even if the PIs are located within the same organization. The application submission process for Project Team PIs uses an abbreviated full application package.

4.3.1. Full Application Components for the Consortium Director

Each application submission must include the completed full application package for this program announcement. See Appendix 1 for a checklist of the full application components.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov submissions only)*:

IMPORTANT: *When completing the SF424 R&R, enter the* ***eBRAP log number*** *assigned during pre-application submission into* ***Block 4a – Federal Identifier****.*

(b) Attachments:

Each attachment of the full application components must be uploaded as an individual file in the format specified and in accordance with the formatting guidelines in the GAI.

- **Attachment 1: Project Narrative (45-page limit): Upload as "ProjectNarrative.pdf".**

  Describe the proposed consortium in detail using the outline below.

  - **Overarching Challenge(s):** State explicitly which overarching challenge(s) in breast cancer the proposed research will address. Describe how a deep, ***definitive*** dive into the overarching challenge(s) or fundamental issue(s) in breast cancer will explore or address the issue in a manner not yet attempted and will fundamentally and significantly transform and disrupt the current breast cancer landscape.

- **Central Hypothesis:** State the consortium's central hypothesis to be tested.
- **Projects and Objectives:** Briefly explain the consortium's proposed projects that the Consortium Director and each Project Team PIs will lead, and explain the objective(s) to be reached by each project. Explain how the projects form a coherent plan to address the consortium's central hypothesis. Identify the key points of interaction between the projects and how such interaction will create synergy to address the overarching challenge(s) more effectively than projects conducted independently.

Consortia should have at least four, but no more than five, project teams, each investigating different projects. The Consortium Director will lead one project, and the Project Team PIs will lead the remaining three or four projects. For each proposed project (either four or five total with one led by the Consortium Director), provide the following details using this outline. Start each project on a separate page:

- **Title:** Provide a title for each project.
- **Project Leader:** Identify the project leader (either the Consortium Director or one of the Project Team PIs) and any key personnel, as appropriate.
- **Background:** Describe in detail the ideas and reasoning on which the proposed research is based. Provide sufficient preliminary data to support the feasibility of the work proposed. The application must demonstrate logical reasoning and provide a sound scientific rationale, as established through a critical review and analysis of published literature. If proposing translational or clinical research, describe the studies showing proof of concept and, if applicable, efficacy in an in vivo system.
- **Hypothesis/Objective:** State the hypothesis to be tested and/or the objective(s) to be reached.
- **Specific Aims:** Concisely explain the project's specific aims.
- **Research Strategy:** Describe the experimental design, methods, and analyses, including appropriate controls, in sufficient detail for evaluation. Explain how this research strategy will meet the research goals and milestones. Address potential pitfalls and problem areas, and present alternative methods and approaches. Applications proposing translational research should provide a well-developed, well-integrated, and detailed research plan that supports the translational feasibility and promise of the approach. If the methodology is new or unusual, provide sufficient details for evaluation. If using human subjects or human biological samples, describe the study population and provide a detailed plan for the recruitment of human subjects or the acquisition of samples. Where relevant, describe the availability of, and access, to the data, human samples, cohort(s), and/or critical reagents (e.g., therapeutic molecules) necessary for the project, and provide appropriate letters of support in Attachment 2: Supporting Documentation. If applicable, describe resources available for the development of sufficient quantities of critical reagents under Good Manufacturing Practices (GMP) guidelines. Describe data reporting procedures and plans to assure that the documentation will support a regulatory filing with the U.S. Food and Drug Administration (FDA) or an equivalent international regulatory agency, if applicable. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.

For clinical research, see Attachment 12 for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study.

- **Clinical Strategy *(if applicable)*: *Only small-scale (e.g., up to and including phase 1 or equivalent) clinical trials are allowed*.** Describe the rationale for the proposed clinical trial. Provide detailed plans for initiating, conducting, and completing the clinical trial during the period of performance. As appropriate, outline a plan for obtaining regulatory approvals necessary to initiate the clinical trial (e.g., active Investigational New Drug (IND), Investigational Device Exemption (IDE), or equivalent status). If an IND or IDE (or other international equivalent) is required, the PI must submit the IND/IDE (or other international equivalent) application to the applicable regulatory agency within 12 months of the award start date. Describe the type of clinical trial the team will perform (e.g., prospective, randomized, controlled), the study phase, and the study model (e.g., single group, parallel, crossover). Outline the proposed clinical trial methodology in sufficient detail to show a clear course of action. Describe potential challenges and alternative strategies where appropriate. Consult appropriate guidelines to ensure relevant aspects of rigorous and reproducible research are adequately planned for and, ultimately, reported.
  - Identify the intervention the clinical trial will test and describe the projected outcomes.
  - Define the study variables and describe how the study team will measure them. Include a description of appropriate controls and the endpoints to be tested.
  - Describe the availability of, and access to, critical reagents (e.g., therapeutic molecules) necessary for the clinical trial, and provide appropriate letters of support in Attachment 2: Supporting Documentation.
  - Identify the study population and specify the number of human subjects the trial will enroll. Describe the access to the study population, recruitment plans and inclusion/exclusion criteria. Provide appropriate letters of support demonstrating access to the study population in Attachment 2: Supporting Documentation. Define each arm/study group of the proposed trial, if applicable, and describe how group assignment will occur. See Attachment 12 for the required strategy for the inclusion of women and minorities appropriate to the objectives of the study.
- **Statistical Plan:** Describe the statistical model and data analysis plan with respect to the study objectives. Ensure the application provides sufficient information to allow for a thorough evaluation of all statistical calculations during review of the application. Include a power analysis to demonstrate that the sample size is appropriate to meet the objectives of the study. Explain any anticipated subgroup analyses and demonstrate that such analyses will be appropriately powered.

- **Attachment 2: Supporting Documentation: Combine and upload as a single file named "Support.pdf".**

There are no page limits for these components unless otherwise noted. Include only components described below; inclusion of items not requested or viewed as an extension of the Project Narrative will result in the removal of those items or may result in administrative withdrawal of the application.

- **References Cited:** List the references cited in the Project Narrative using a standard reference format (include URLs, if available).

- **List of Abbreviations, Acronyms and Symbols:** Provide a list of abbreviations, acronyms and symbols.
- **Facilities, Existing Equipment and Other Resources:** Describe the facilities and equipment available for performance of the proposed project; include any additional facilities or equipment proposed for acquisition at no cost to the award. Indicate whether government-furnished facilities or equipment are proposed for use. If so, reference the original or present government award under which the facilities or equipment items are now accountable. There is not a standardized form for this information.
- **Publications and/or Patents:** Include a list of relevant publication URLs and/or patent abstracts. If articles are not publicly available, then copies of up to five published manuscripts may be included in Attachment 2. Extra items will not be reviewed.
- **Letters of Support:** Provide individual letters signed by collaborating individuals and/or organizational officials demonstrating that the PI has the support and resources necessary for the proposed work. Letters from the PI's Department Chair, or appropriate organization official, should also confirm that the PI(s) meet eligibility criteria. If applicable, provide a letter of support, signed by the lowest-ranking person with approval authority, confirming participation of intramural DOW collaborator(s) and/or access to military populations, databases or DOW resources. If applicable, provide a letter of support signed by the VA Facility Director(s), or an individual designated by the VA Facility Director(s), confirming access to VA patients, resources and/or VA research space.
- **Consumer Advocate Letters of Commitment:** Provide a signed letter by each project's consumer advocate confirming their commitment to participate in the proposed project.
- **Sex as a Biological Variable (SABV) Strategy (two-page limit is recommended):** Describe the strategy for how sex will be considered as a biological variable. This strategy should include a brief discussion of what is currently known regarding sex differences in the applicable research area. Clearly articulate how sex as a biological variable will be factored into the data analysis plan and how data will be collected and disaggregated by sex. If needed, provide a strong rationale for proposing a single-sex study, based on justification from scientific literature, preliminary data or other relevant considerations. Refer to the CDMRP Directive on Sex as a Biological Variable in Research for additional information.

- **Attachment 3: Technical Abstract (one-page limit): Upload as "TechAbs.pdf".**

  Write the technical abstract using the outline below. Clarity and completeness within the space limits are highly important.

  - **Background:** Present the ideas and reasoning behind the proposed consortium's research.
  - **Overarching Challenge(s):** State the overarching challenge(s) in breast cancer that the proposed research will address. Describe how a deep, **definitive** dive into the overarching challenge(s) or fundamental issue(s) in breast cancer will explore or address the issue in a manner not yet attempted and will fundamentally and significantly transform and disrupt the current breast cancer landscape. Simply identifying an overarching challenge is not sufficient.

- **Central Hypothesis:** State the consortium's central hypothesis to be tested.
- **Projects and Objectives:** Briefly explain the projects the Consortium Director and Project Team PIs will each lead and the objective(s) each project will reach. Explain how the projects will support the consortium's central hypothesis.
- **Innovation:** Briefly describe how the consortium will change existing paradigms or develop new paradigms.
- **Impact:** Explain how the consortium will make a transformative impact on the lives of individuals with, and/or at risk for, breast cancer.
- **Military Relevance:** Describe how the study is relevant to military health.

- **Attachment 4: Lay Abstract (one-page limit): Upload as "LayAbs.pdf".**

  The lay abstract should address the points outlined below ***in a manner that is readily understood by readers without a background in science or medicine.*** Avoid overuse of scientific jargon, acronyms and abbreviations. ***Do not duplicate the technical abstract.***

  - Clearly describe the scientific rationale, objectives and aims of the application.
  - Describe the ultimate applicability and impact of the research.
    - What overarching challenge(s) in breast cancer will this research address?
    - How will the consortium change existing paradigms or develop new paradigms?
    - What types of patients or at-risk individuals will the outcomes of the consortium help, and how will it help them?
    - What are the potential clinical applications, benefits and risks?
    - What is the projected time it may take to achieve a patient-related outcome?
    - What is the potential transformative impact of this study on individuals with, and/or at risk for, breast cancer?
- How is the proposed research relevant to Service Members, Veterans, and their Families?
- **Attachment 5: Statement of Work (eight-page limit): Upload as "SOW.pdf".** Refer to eBRAP for the Suggested SOW Format.

  For guidance on preparing the SOW, refer to either the Example: Assembling a Clinical Research and/or Clinical Trial Statement of Work or Example: Assembling a Generic Statement of Work, whichever is most appropriate for the proposed effort. Include milestones for data or research resource(s) sharing.

  Each PI must submit an identical copy of a jointly created SOW. The specific contributions of the Consortium Director and each Project Team PI should be clearly noted for each task.
- **Attachment 6: Impact Statement (300 words or less recommended; one-page limit): Upload as "Impact.pdf".**

  The statement should address the points outlined below written ***in a manner that is readily understood by readers without a background in science or medicine. DO NOT restate the research strategy as part of the Impact Statement.***

Articulate how the proposed consortium's research will make a transformative impact on the lives of individuals with, and/or at risk for, breast cancer and will significantly advance and accelerate progress toward the BCRP's mission of ending breast cancer. Applications proposing research that represents an incremental advance in breast cancer do not meet the intent of this award mechanism.

- **Attachment 7: Innovation Statement (one-page limit): Upload as "Innovation.pdf".**
  - Describe how the proposed consortium's research will introduce a new paradigm, look at existing problems from new perspectives or exhibit other highly creative qualities.
  - Describe the innovations and technical solutions that the consortium will implement to accomplish the consortium's overall research goals.
  - To support the pursuit of innovative ideas, describe the plan for potential "seed projects" that may emerge over the course of the award that will allow the consortium teams to pursue high-risk/high-reward ideas.
- **Attachment 8: Consortium Plan (eight-page limit): Upload as "ConsortiumPlan.pdf".**
  - **Consortium Team and Environment:** Describe how the consortium is composed of an integrated team of preeminent investigators and advocates from appropriate disciplines and institutions. Explain how the consortium brings different disciplines together with one overarching plan to address breast cancer with an ecologic approach. Describe how the Consortium Director's research experience and leadership skills make them well qualified to serve as Consortium Director. In addition, describe how each Project Team PI will bring a different strength and/or expertise to the application. Describe how the combined expertise of the Consortium Director, each Project Team PI and consumer advocates in the consortium will better address the research question, and explain why the work should be done together rather than through separate efforts. Explain how the consumer advocates will represent the perspective of the patient population(s) most relevant to the consortium's proposed work. Include an organizational chart identifying the roles of all team members, including consumer advocates. Describe the research environments and how each of the facilities and resources at all of the institutions will support the research requirements and the projects.
  - **Integration Plan:** Present a detailed plan that describes the integration across the consortium in all aspects, administration, logistics and substance. Describe the substantive integration across and among teams that are necessary to the work. Provide a detailed explanation of the substantive research processes that will integrate.
  - **Research Management Plan:** Present a detailed research management plan that identifies critical milestones, outlines the innovations and technical solutions for accomplishing the research goals and explains the plan for translation to individuals with, and/or at risk for, breast cancer.
  - **Consortium Management Plan:** Present an overall management plan to facilitate group interactions, adherence to regulatory requirements, administrative interactions, and oversight by advisory board(s) and/or steering committee(s). Provide an effective and coordinated administrative management plan that describes how the consortium will be organized and managed. Specify the processes and tools the

consortium will use for project meeting scheduling, reviews of research findings, authorship of publications arising from the consortium's work, and other issues of common concern to the consortium and its investigators. The administrative management plan must also describe procedures that maximize the use of resources and eliminate unnecessary duplication of efforts. The application should include a program manager who will guide the overall administrative management of the consortium.

- **Communication Plan:** Provide a detailed communication plan for effective communication between and among consortium team members and their institutions. Provide a strategy for data sharing in real time, using information technologies that facilitate timely and effective communication and cooperation among consortium members. Identify the individual(s) who will maintain the data sharing and communications technologies.

- **Attachment 9: Consumer Advocate Statement (two-page limit): Upload as "ConsumerAdvocate.pdf".**

  The Consortium Director should write the Consumer Advocate Statement. Provide the name(s) of at least one consumer advocate for each project team and their affiliation with a breast cancer advocacy organization(s). Explain how the consumer advocates contributed to the consortium's conception and design. Describe the integral roles that the consumer advocates will play in the planning, design, implementation, evaluation of the research, ongoing discussion, decisions and oversight, program evaluation, and dissemination of information to the public. Describe how the consumer advocates' knowledge of current breast cancer issues and how their background and/or training in breast cancer research will contribute to the consortium. Explain how the consumer advocates' experience and expertise will be integrated into the research projects and management of the consortium.

- **Attachment 10: Research Sharing Plan (two-page limit): Upload as "Sharing.pdf".** Describe the type of data or research resources to be made publicly available as a result of the proposed work. Describe the mechanism (e.g., direct sharing, repository, mixed mode) by which data and resources generated during the period of performance will be shared with the research community and other affected communities, including clinical research participants. Specifically, describe a plan to make experimental platforms, tissue samples, and other data and resources developed as a part of the proposed research project available to the scientific community. If applicable, include the name of the repository(ies) where scientific data and resources arising from the proposed study will be archived. Identify and provide the rationale for any data or resources that will not be shared (e.g., for intellectual property, feasibility, cost, or other considerations). The plan should also protect participant privacy, confidential and proprietary data, and performer/third-party intellectual property. Provide a milestone plan for disseminating data/results including when data and resources will be made available to other users. In cases where the study participant could potentially derive medical or other benefit from the information, explain whether the results of screening and/or study participation will be shared with the participant or their primary care provider, including results from any screening or diagnostic tests performed as part of the study.

  Do not submit a copy of the National Institutes of Health (NIH) Data Management and Sharing Plan or duplicate the Data Management Plan which will be requested only after a recommendation for funding is made.

Refer to the CDMRP Directive on Sharing Data and Research Resources for more information about the CDMRP's expectations for making data and research resources publicly available.

- **Attachment 11: Post-Award Transition Plan (three-page limit): Upload as "Transition.pdf".** Provide information on potential methods and strategies to move the consortium's findings to the next phases of development and/or clinical use following the successful completion of the award. Articulate this information for the overall effort as well as the individual projects. ***The post-award transition plan should:***
  - Include a detailed plan for distribution of findings to the breast cancer community.
  - Name the consortium's anticipated research outcomes including knowledge products and/or clinical products for development. A "knowledge product" is a non-materiel product that aims to transition into medical practice, training, tools or to support materiel solutions; and educates or impacts behavior throughout the continuum of care, including primary prevention of negative outcomes.
  - Include a timeline with defined milestones describing the logical next steps to advance the research outcome to the next stage of clinical development/implementation/dissemination. Include steps regarding regulatory agency approval as appropriate.
  - Describe collaborations and other resources (e.g., clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees) that are in place or will be established to execute the steps described above. As appropriate, include a discussion of the funding strategy necessary to transition the research outcome to the next level of investigation, development and/or commercialization. The discussion should include potential opportunities for securing funding through commercial sponsorship, venture capital, federal or nonfederal funding opportunities, or other relevant resources.
  - As appropriate, discuss ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award. Include a plan for resolving intellectual and material property issues among participating organizations. If the intellectual property rights are not owned by the applicants, PIs or a member of the study team, describe the planned next steps necessary to make the product available to the target population.
- **Attachment 12: Inclusion of Women and Minorities (six-page limit): Upload as "Inclusion.pdf". (Attachment 12 is only applicable and required for applications that propose clinical research and/or clinical trials.)**

  Describe the strategy for the inclusion of women and minorities appropriate to the objectives of the study, including a description of the composition of the proposed study population in terms of sex, racial, and ethnic group, and an accompanying rationale for the selection of subjects. Provide an anticipated enrollment table(s) for the inclusion of women and minorities using the Public Health Service (PHS) Inclusion Enrollment Report, a three-page fillable PDF form, that can be downloaded from eBRAP. The enrollment table(s) should be appropriate to the objectives of the study with the proposed enrollment distributed on the basis of sex, race, and ethnicity. Studies utilizing human biospecimens or datasets that cannot be linked to a specific individual, ethnicity, or race (typically classified as exempt from Institutional Review Board [IRB] review) are exempt from this requirement.

- **Attachment 13: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".** All extramural applicants must complete and submit the Required Representations document available on eBRAP.
- **Attachment 14: Suggested Intragovernmental/Intramural Budget Form *(if applicable)*: Upload as "IGBudget.pdf".** If an intramural DOW organization will be a collaborator in the performance of the project, complete a separate budget for that organization using the Suggested Intragovernmental/Intramural Budget form available on eBRAP.

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal, as found within the GAI.

Grants.gov	eBRAP.org
i. Research & Related Senior/Key Person Profile (Expanded) ○ **Biographical Sketch** *Biographical sketches or equivalent must be submitted for the breast cancer consumer advocates.* ○ **Current/Pending Support** *Intragovernmental applicants must include their internally supported research and development programs.*	
ii. Research & Related Budget *The Consortium Director and Project Team PIs must have separate budgets and justifications specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Consortium Director should not include budget information for Project Team PIs, or vice versa, even if they are located within the same organization. Refer to **Section 3.3, Funding Details**, for detailed budget information.*	
iii. Project/Performance Site Location(s)	
iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*	

4.3.2. Full Application Components for the Project Team PIs

Refer to the equivalent attachment above for details specific to each of the following application components. See Appendix 1 for a checklist of the full application components required for the Project Team PIs.

(a) SF424 Research & Related Application for Federal Assistance Form *(Grants.gov Submissions Only)*:

(b) Attachments:

- **Attachment 5: Statement of Work (eight-page limit): Upload as "SOW.pdf".** Each PI must submit an identical copy of a jointly created SOW.
- **Attachment 13: Representations *(Grants.gov submissions only)*: Upload as "RequiredReps.pdf".**
- **Attachment 14: Suggested Intragovernmental/Intramural Budget Form: Upload as "IGBudget.pdf".**

(c) Additional Application Materials:

The following are additional forms for application submission. Follow the instructions specific to the submission portal found within the GAI.

Grants.gov	eBRAP.org

i. Research & Related Senior/Key Person Profile (Expanded)

- **Biographical Sketch**

  Biographical sketches or equivalent must be submitted for the breast cancer consumer advocates.

- **Current/Pending Support**

  Intragovernmental applicants must include their internally supported research and development programs.

ii. Research & Related Budget

The Consortium Director and Project Team PIs must have separate budgets and justifications specific to their distinct portions of the effort that the applicant organization will submit as separate Grants.gov or eBRAP application packages. The Project Team PIs should not include budget information for the Consortium Director, or vice versa, even if they are located within the same organization. Refer to Section 3.3, Funding Details, for detailed budget information.

iii. Project/Performance Site Location(s)

iv. Research & Related Subaward Budget Attachment(s) *(if applicable, Grants.gov submissions only)*

4.4. Other Application Elements

Oral Presentation: PIs named in applications selected for Programmatic Review, Stage 2, must give an oral presentation (see Section 6.2.3, Programmatic Review). This presentation will take place in the National Capital Area or virtually, at the discretion of the government, and is tentatively scheduled for March 2027. ***Only the invited PIs (the Consortium Director and the three or four Project Team PIs) and one consumer advocate may attend.***

The presentation will consist of the following, with total presentation time not to exceed 45 minutes:

- A three- to five-minute introductory talk by the Consortium Director consisting of no more than five slides.
- For each project, a five- to seven-minute talk by the Project Team PI or Consortium Director who is leading the project, consisting of no more than five slides.
- A five-minute talk by the consumer advocate consisting of no more than five slides.
- A five-minute summary presentation by the Consortium Director consisting of no more than five slides.

Following the presentation, there will be a 30-minute question-and-answer session with the Programmatic Panel members. The questions below will be the topics for discussion during the presentation and the question-and-answer session. Teams invited to Programmatic Review, Stage2, must prepare a presentation that specifically addresses the following four questions within the total presentation time of no more than 45 minutes, without addressing specific aspects of the application:

- What conceptual, intellectual, or scientific barriers do you consider most urgent to overcome in order to end breast cancer, and how will your consortium address them?
- How will the consortium's team-based approach challenge existing paradigms or develop new paradigms that will fundamentally and significantly transform and disrupt the present breast cancer landscape?
- How will your consortium take a team-based, integrated approach and make a transformative impact in people's lives?
- How will your consortium create an environment that fosters innovation?

If recommended for funding, a data management plan compliant with Section 3.c, Enclosure 3, DoD Instructions 3200.12 will be requested.

The government reserves the right to request a revised budget, budget justification and/or additional information for applications recommended for funding.

5. Submission Requirements

5.1. Location of Application Package

Download the application package components for HT942526BCRPTBCCA from Grants.gov or eBRAP, depending on which submission portal will be used.

5.2. Unique Entity Identifier and System for Award Management

The applicant organization must be registered as an entity in the System for Award Management (SAM), SAM.gov, and receive confirmation of an "Active" status before submitting an application through Grants.gov. Organizations must include the unique entity identifier (UEI) generated by the SAM in applications to this funding opportunity and maintain an active registration in the SAM at all times during which it has an active Federal award or an application under consideration.

5.3. Submission Instructions

The CDMRP uses two portal systems to accept pre- and full application submissions. The workflow below shows which portal system to use for pre- and full application submissions, respectively.

Application Submission Workflow



5.3.1. Pre-Application Submission

All pre-application components must be submitted by the Consortium Director through eBRAP including the submission of contact information for each Project Team PI.

During the pre-application process, eBRAP assigns each submission a unique log number. This unique log number is required during the full application submission process. The eBRAP log number, application title and all information for the PI, Business Official(s), performing organization, and contracting organization must be consistent throughout the entire pre-application and full application submission process. Inconsistencies may delay application processing and limit or negate the ability to view, modify and verify the application in eBRAP. Contact the eBRAP Help Desk if any changes need to be made.

After the Consortium Director confirms submission of the pre-application, the Project Team PIs will be notified of the pre-application submission via an email from eBRAP. ***The Project Team PIs must follow the instructions provided in the email to associate the partnering pre-application with their eBRAP account.*** If not previously registered, the Project Team PIs must register in eBRAP.

Project Team PIs should not initiate a new pre-application based on the same research project submitted by the Consortium Director. Project Team PIs are urged to associate the partnering pre-application with their eBRAP account as soon as possible. If this is not completed by the full application deadline:

- Any intramural Project Team PI will not be able to submit their full application package components to eBRAP.
- The Project Team PIs will not be able to view and modify their full application during the verification period in eBRAP.

When starting the pre-application, PIs should select a Mechanism Option appropriate to their pre-application:

Application Includes:	Select Mechanism Option:
No Clinical Trial	No Option
Clinical Trial	Clinical Trial

5.3.2. Full Application Submission

Grants.gov Submissions: Full applications from extramural organizations *must* be submitted through the Grants.gov Workspace.

eBRAP Submissions: Only intramural DOW organizations may submit full applications through eBRAP.

5.3.3. Applicant Verification of Full Application Submission in eBRAP

Independent of the submission portal, once the full application is submitted, it is transmitted to and processed in eBRAP; the transmission to eBRAP may take up to 48 hours. At this stage, the PI and organizational representatives will receive an email from eBRAP instructing them to log in to eBRAP to review, modify and verify the full application submission. ***The Project Narrative and Research & Related Budget Form cannot be changed after the application submission deadline.*** Other application components, including subaward

budget(s) and subaward budget justification(s), may be changed until the application verification period ends. The full application cannot be modified once the application verification period ends.

5.4. Submission Dates and Times

The pre-application and full application submission process should be started early to avoid missing deadlines. Regardless of submission portal used, all pre- and full application components must be submitted by the deadlines stipulated in this program announcement. There are no grace periods for deadlines; failure to meet submission deadlines will result in application rejection. ***The DHACA cannot make allowances/exceptions for submission problems encountered by the applicant.***

Submission dates and times are specified in Section 1, Basic Information.

5.5. Intergovernmental Review

Not applicable for this funding opportunity.

6. Application Review Information

6.1. Application Compliance Review

Submitting applications that propose essentially the same research project to different funding opportunities within the same program and fiscal year is prohibited and will result in administrative withdrawal of the duplicative application(s).

While it is allowable to propose similar research projects to different programs within the CDMRP or to other organizations, duplication of funding or accepting funding from more than one source for the same research is prohibited. See the CDMRP's Directive on Research Duplication.

Including classified research data within the application and/or proposing research that may produce classified outcomes or outcomes deemed sensitive to national security concerns, may result in application withdrawal.

Members of the FY26 BCRP Programmatic Panel must not be involved in any pre-application or full application including, but not limited to, concept design, application development, budget preparation and the development of any supporting documentation, including personal letters of support/recommendation for the research and/or PI. Programmatic panel members ***may*** provide letters to confirm PI eligibility and access to laboratory space, equipment and other resources necessary for the project if that is part of their regular roles and responsibilities (e.g., as Department Chair). ***A list of the FY26 BCRP Programmatic Panel members can be found on the CDMRP website.***

Additional restrictions and associated administrative responses are outlined in Section 9.2, Administrative Actions.

6.2. Review Criteria

6.2.1. Pre-Application Screening Criteria

To determine the merits of the pre-application and the relevance to the mission of the Defense Health Program and the BCRP, pre-applications will be screened based on the following criteria:

- To what degree the proposed research will fundamentally and significantly transform and disrupt the present breast cancer landscape.
- To what degree the consortium brings different disciplines together with one overarching plan to address breast cancer with an ecologic approach.
- To what degree the proposed research is innovative and introduces brand-new paradigms in breast cancer.
- To what degree the consortium's proposed deep, definitive dive into one (or more) of the overarching challenge(s) or other fundamental issue(s) in breast cancer will explore or address the issue in a manner not yet attempted.
- To what degree the proposed research will make a transformative impact on the lives of individuals with, and/or at risk for, breast cancer and significantly accelerate progress toward ending breast cancer.
- Whether the overall organization and roles of key personnel, including consumer advocates, are described and well-reasoned.

- To what degree the consortium team is integrated to address an overarching problem in breast cancer in a way that could not be accomplished by a single investigator or group.
- To what degree the proposed consortium will be integrated in all aspects, including administration, logistics, and substance.

6.2.2. Peer Review Criteria

To determine technical merit, all applications will be evaluated individually according to the following **scored criteria**, which are of equal importance:

- **Impact**
  - To what degree the proposed consortium's research will make a transformative impact on the lives of individuals with, and/or at risk for, breast cancer. Research benefiting a single subtype is considered impactful as long as the impact for that subtype is high.
  - To what degree the proposed consortium's research will significantly advance and accelerate progress toward the BCRP's mission of ending breast cancer.
  - To what degree a deep, definitive dive into the overarching challenge(s) or fundamental issue(s) in breast cancer will explore or address the issue in a manner not yet attempted and will fundamentally and significantly transform and disrupt the current breast cancer landscape.
- **Research Strategy and Feasibility**
  - To what degree the proposed overall research strategy to address the consortium's central hypothesis is appropriate and feasible.
  - To what degree the application identifies the key points of interaction between the projects and demonstrates that such interaction will create synergy to address the overarching challenge(s) more effectively than projects conducted independently.
  - How well the scientific rationale supports the proposed research and its feasibility for each proposed project, as demonstrated by a critical review and analysis of published literature, logical reasoning, and preliminary data.
  - How well the application develops the hypothesis, objective, and specific aims for each proposed project.
  - How well the application develops the experimental design, methods, and analyses for each proposed project, and to what degree the design, methods and analyses support completion of the specific aims.
  - How well the application acknowledges potential pitfalls and problem areas and addresses alternative methods and approaches for each proposed project.
  - How well the application describes an appropriate plan for recruitment of human subjects or acquisition of human biological samples, if applicable, for each proposed project. Whether there is documented availability of, and access to, data, samples, cohort(s) and/or critical reagents, where relevant.
  - If applicable, whether there are resources available for the development of sufficient quantities of critical reagents under GMP for each proposed project.
  - If applicable, whether there is an appropriate plan for data reporting and documentation to support a regulatory filing with the FDA or an equivalent international regulatory agency for each proposed project.

- How well the research is designed to achieve reproducible and rigorous results, including the choice of model and the endpoints/outcomes to be measured for each proposed project.
- For each clinical research project other than clinical trials, whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed research.
- For each clinical research project other than clinical trials, whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study or whether the justification for a single-sex study is sufficiently strong for each proposed project.

- **Statistical Plan**
  - To what degree each proposed project provides an appropriate statistical plan, including power analysis.
  - If applicable, whether the clinical trial design includes enough statistical power to meet the objectives of the study.
- **Consortium Team**
  - To what degree the Consortium Director's research experience and leadership skills make them well-qualified for the role.
  - To what degree the Project Team PIs bring different strengths and/or expertise to the application.
  - To what degree the consortium brings different disciplines together with one overarching plan to address breast cancer with an ecologic approach.
  - How the consortium team's background and expertise are appropriate to accomplish the proposed projects.
  - How the consortium team's combined expertise will better address the research question than through separate efforts.
  - How appropriate the level of effort is for the Consortium Director, who must commit a minimum level of time and effort of 25% to direct and manage the consortium, as well as to lead their own project team.
  - Whether each Project Team PI will commit an appropriate level of effort.
  - To what degree the consumer advocates contributed to the consortium conception and design.
  - Whether the consortium team includes at least one consumer advocate per project; and to what degree the consumer advocates will play an integral role in the planning, design, implementation, evaluation of the research, ongoing discussion, decisions and oversight, program evaluation, and dissemination of information to the public.
  - To what degree the consumer advocates' knowledge of current breast cancer issues and their background and/or training in breast cancer research will contribute to the proposed consortium.
  - How well the consumer advocates represent the perspectives of the patient population(s) most relevant to the consortium's proposed work.

- **Consortium Plan**
  - To what degree the integration plan demonstrates the necessary integration across the consortium in all aspects, including administration, logistics and substance.
  - To what degree the application describes substantive integration across and among teams and provides a detailed explanation of the research processes that it will integrate.
  - To what degree the consortium's research management plan identifies critical milestones, innovations and technical solutions to accomplish the research goals; and explains the translation of these solutions to individuals with, and/or at risk for, breast cancer.
  - To what degree the consortium management plan will facilitate group interactions, adherence to regulatory requirements, administrative interactions and oversight.
  - How well the application describes an effective and coordinated administrative management plan for organization and management of the consortium, and procedures to maximize the use of resources and eliminate unnecessary duplication of efforts.
  - How well the application specifies processes and tools utilized for project meeting scheduling, reviews of research findings, authorship of publications and other issues of common concern to the consortium and its investigators.
  - How well the application describes a detailed communication plan between and among consortium team members and their institutions.
  - How well the application's strategy for sharing data in real time and using information technologies will facilitate timely and effective communication and cooperation among consortium members.
  - Whether the application identifies the individual(s) who will maintain the data sharing and communication technologies.
- **Post-Award Transition Plan**
  - Whether the application has an appropriate plan to distribute the findings to the breast cancer community.
  - Whether the application describes a feasible schedule and milestones for bringing outcomes to the next stage of clinical development, implementation and/or dissemination.
  - To what degree the collaborations and other resources (e.g., clinical partners, commercial partners, manufacturing partners, clinical practice guideline development/execution committees) intended to help advance the research outcome(s) are established and/or achievable.
  - To what degree ownership rights/access to the intellectual property necessary for the development and/or commercialization of products or technologies supported with this award are considered and planned for.
- **Clinical Strategy *(only applicable if a clinical trial is proposed)***
  - Whether the type of clinical trial and study model are appropriate to meet the project's objectives.
  - How well the clinical trial is designed with appropriate study variables, controls and endpoints.

- How well the application describes the availability of, and access to, critical reagents (e.g., therapeutic molecules) necessary for the clinical trial.
- How well the application demonstrates access to the study population and describes appropriate recruitment plans and inclusion/exclusion criteria.
- Whether the clinical trial design, methods and analysis plan meet the requirements for applying for and obtaining active IND, IDE or equivalent status, if appropriate.
- Whether the application appropriately identifies potential challenges and alternative strategies.
- Whether the strategy for the inclusion of women and minorities and the distribution of proposed enrollment are appropriate for the proposed research.
- Whether the strategy for considering sex as a biological variable is appropriate to the objectives of the study, or whether the justification for a single-sex study is sufficiently strong.

- **Innovation**
  - To what degree the proposed consortium's research will introduce a new paradigm, look at existing problems from new perspectives or exhibit other highly creative qualities.
  - How well the application describes the innovations and technical solutions the consortium will implement to accomplish the overall research goals.
  - How well the application describes a plan for potential "seed projects" that may emerge over the course of the award to allow the pursuit of high-risk/high-reward ideas.

In addition, the following criteria will also contribute to the overall evaluation of the application, but will not be individually scored and are therefore termed **unscored criteria**:

- **Research Sharing Plan**
  - To what extent the plan for sharing of project data and research resources is appropriate and reasonable and includes dissemination to affected communities, study participants and/or the scientific community. If applicable, whether specific repository(ies) are named where data and research resources arising from the project will be stored.
- **Budget**
  - Whether the budget is appropriate for the proposed research.
- **Environment**
  - To what extent the scientific environment and level of institutional support is appropriate for the proposed research project.
  - How well the research requirements are supported by the availability of and accessibility to facilities and resources.
- **Application Presentation**
  - To what extent the writing, clarity and presentation of the application components influence the review.

6.2.3. Programmatic Review

To make funding recommendations and select the application(s) that, individually or collectively, will best achieve the program objectives, the following criteria are used by programmatic reviewers:

- Ratings and evaluations of peer reviewers
- Relevance to the priorities of the FY26 BCRP, as evidenced by the following:
    - **Stage 1:** During the first stage of programmatic review, the FY26 BCRP Programmatic Panel will evaluate applications for invitation to Stage 2 using the following criteria:
        - Adherence to the intent of the funding opportunity
        - Program portfolio composition
        - Relative impact
        - Relative innovation
    - **Stage 2 (Oral Presentation):** During the second stage of programmatic review, the FY26 BCRP Programmatic Panel will use the following criteria:
        - Understanding of conceptual or intellectual or scientific barriers in breast cancer and articulation of how the consortium will address them.
        - Articulation of how the consortium's team-based approach will challenge existing paradigms or develop new paradigms that will fundamentally and significantly transform and disrupt the present breast cancer landscape.
        - Articulation of how the consortium will take a team-based, integrated approach and make a transformative impact in people's lives.
        - Consortium's capability to create an environment that fosters innovation.

6.3. Application Review and Selection Process

6.3.1. Pre-Application

Following the pre-application screening, Consortium Directors will be notified as to whether they are invited to submit full applications. The estimated date when PIs can expect to receive notification of an invitation to submit a full application is indicated in Section 1, Basic Information about the Funding Opportunity. No feedback (e.g., a critique of the pre-application's strengths and weaknesses) is provided at this stage. Because the invitation to submit a full application is based on the contents of the pre-application, investigators should not change the title or research objectives after the pre-application is submitted.

6.3.2. Full Application

All applications are evaluated by scientists, clinicians and consumers in a two-tier review process. The first tier is **peer review**, the evaluation of applications against established criteria to determine technical merit, where each application is assessed for its own merit, independent of other applications. The second tier is **programmatic review**, a comparison-based process in which applications with high scientific and technical merit are further evaluated for programmatic relevance. Final recommendations for funding are subject to review and approval by a designated official. ***The highest-scoring applications from the first tier of review are not***

automatically recommended for funding. Funding recommendations depend on various factors as described in Section 6.2.3, Programmatic Review. Additional information about the two-tier process used by the CDMRP can be found on the CDMRP website.

Funding of applications received is contingent upon the availability of federal funds for this program, the number of applications received, the quality and merit of the applications as evaluated by peer and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds.

6.4. Risk, Integrity and Performance Information

Prior to making an assistance agreement award where the federal share is expected to exceed the simplified acquisition threshold, as defined in the Code of Federal Regulations, Title 2, Part 200.1 (2 CFR 200.1), over the period of performance, the federal awarding agency is required to review and consider any information about the applicant that is available in the SAM.

An applicant organization may review the SAM and submit comments on any information currently available about the organization that a federal awarding agency previously entered. The federal awarding agency will consider any comments by the applicant, in addition to other information in the designated integrity and performance system, in making a judgment about the applicant's integrity, business ethics and record of performance under federal awards when determining a recipient's qualification prior to award, according to the qualification standards of the Department of Defense Grant and Agreement Regulations (DoDGARs), Section 22.415.

In accordance with National Security Presidential Memorandum-33 and all associated laws, all fundamental research funded by the DOW must be evaluated for affiliations with foreign entities. All applicant organizations must disclose foreign affiliations of all key personnel named on applications. Failure to disclose foreign affiliations of key personnel shall lead to withdrawal of recommendations to fund applications. Applicant organizations may be presented with an opportunity to mitigate identified risks, particularly those pertaining to influence from foreign entities specified in law. Implementation of mitigation discussions and utilization of the DOD Component Decision Matrix must decrease risk of foreign influence in accordance with the above-mentioned laws and guidance prior to award.

7. Federal Award Notices

For each compliant full application received, the organizational representative(s) and PI will receive email notification when the funding recommendations are posted to eBRAP, typically within 6 weeks after programmatic review. At this time, each PI will receive a peer review summary statement on the strengths and weaknesses of the application and an information paper describing the application receipt and review process for the BCRP award mechanisms. The information papers and a list of organizations and PIs recommended for funding are also posted on the program's page within the CDMRP website. After all awards are made, the CDMRP includes individual award information in a searchable database.

If an application is recommended for funding, after the email notification is posted to eBRAP, a government representative will contact the person authorized to negotiate on behalf of the recipient organization.

Only an appointed DHACA Grants Officer may obligate the government to the expenditure of funds to an extramural organization. No commitment on the part of the government should be inferred from discussions with any other individual. ***The award document signed by the Grants Officer is the official authorizing document (i.e., assistance agreement).***

Intragovernmental obligations of funding will be made according to the terms of a negotiated Inter-Agency Agreement and managed by a CDMRP Science Officer.

Funding obligated to ***intragovernmental and intramural DOW organizations*** will be sent through the Military Interdepartmental Purchase Request (MIPR), Funding Authorization Document (FAD) or Direct Charge Work Breakdown Structure processes. Transfer of funds is contingent upon appropriate safety and administrative approvals. Intragovernmental and intramural DOW investigators and collaborators must coordinate receipt and commitment of funds through their respective Resource Manager/Task Area Manager/Comptroller or equivalent Business Official.

An organization may, at its own risk and without the government's prior approval, incur obligations and expenditures to cover costs up to 90 days before the beginning date of the initial budget period of a new award.

8. Post-Award Requirements

8.1. Administrative and National Policy Requirements

Applicable requirements in the DoDGARs found in 32 CFR, Chapter I, Subchapter C, and 2 CFR, Chapter XI, apply to grants and cooperative agreements resulting from this program announcement.

The GAI contains information regarding administrative requirements and national policy requirements.

Refer to full text of the latest DoD R&D Terms and Conditions and the DHACA Terms and Conditions for further information.

If there are delinquencies in technical reporting requirements for any existing DHA or U.S. Army Medical Research and Development Command awards at the applicant organization, DHACA will not issue any new awards to the applicant organization until all delinquent reports have been submitted.

Applications recommended for funding that involve animals, human data, human specimens, human subjects or human cadavers must be reviewed for compliance with federal animal and/or human subjects protection requirements and must be approved by the DHA R&D Office of Research and Regulatory Compliance (ORRC), prior to implementation. This administrative review requirement is in addition to the local Institutional Animal Care and Use Committee (IACUC), IRB or Ethics Committee (EC) review.

Funded trials are required to post a copy of the informed consent form used to enroll subjects on a publicly available federal website in accordance with federal requirements described in 32 CFR 219. Additionally, the CDMRP requires all funded clinical trials to register and submit study results on ClinicalTrials.gov.

8.2. Reporting

For all applications, annual technical progress reports as well as a final technical progress report will be required. For applications proposing a clinical trial, quarterly and annual technical progress reports, as well as final technical progress reports, will be required. Annual and final technical progress reports must be prepared in accordance with the Research Performance Progress Report (RPPR).

The Award Terms and Conditions will specify whether additional and/or more frequent reporting is required.

Inclusion Enrollment Reporting: ***(only required for clinical research studies and clinical trials):*** Enrollment reporting on the basis of sex, race, and/or ethnicity using the PHS Inclusion Enrollment Report will be required with each annual and final progress report. The PHS Inclusion Enrollment Report is available on eBRAP.

Award Expiration Transition Plan: An Award Expiration Transition Plan, using the template available on eBRAP, must be submitted with the final progress report

Awards resulting from this program announcement may entail additional reporting requirements related to recipient integrity and performance matters. Recipient organizations that have federal contract, grant and cooperative agreement awards with a cumulative total value greater than $10M are required to provide information to the SAM about certain civil, criminal and

administrative proceedings that reached final disposition within the most recent 5-year period and that were connected with their performance of a federal award. These recipients are required to disclose, semiannually, information about criminal, civil and administrative proceedings as specified in the applicable Representations.

8.3. Additional Requirements

The Consortium Director, Project Team PIs and consumer advocates must attend and present an update on progress toward accomplishing research milestones and goals of the consortium and each project at an annual IPR meeting held at the conclusion of year 1 and every subsequent year in the period of performance. For planning purposes, the team should assume that in-person meetings will be held in the National Capital Area or virtually, at the discretion of the government. Members of the BCRP Programmatic Panel, CDMRP staff, and the DHACA Grants Officer will attend.

Unless otherwise restricted, changes in the PI or organization will be allowed on a case-by-case basis, provided the intent of the award mechanism is met.

The organizational transfer of an award supporting a clinical trial is strongly discouraged and in most cases will not be allowed. Approval of a transfer request will be on a case-by-case basis at the discretion of the Grants Officer.

An organizational transfer of an award will not be allowed in the last year of the original period of performance or any extension thereof.

9. Other Information

9.1. Program Announcement Version

Questions related to this program announcement should refer to the program name, the program announcement name and the program announcement version code CD26_01d.

9.2. Administrative Actions

After receipt of full applications, the following administrative actions may occur.

9.2.1. Rejection

The following will result in administrative rejection of the pre-application:

- Preproposal Narrative is missing.

The following will result in administrative rejection of the full application:

- Submission of an application for which a letter of invitation was not issued.
- The Project Narrative is missing.
- The Budget is missing.

9.2.2. Modification

- Pages exceeding the specified limits will be removed prior to reviewing all documents.
- Documents not requested will be removed.

9.2.3. Withdrawal

The following may result in administrative withdrawal of the full application:

- A member of the FY26 BCRP Programmatic Panel is named as being involved in the development or execution of the research proposed or is found to have assisted in the pre-application or application processes.
- The application includes the name(s) of personnel from either of the CDMRP peer or programmatic review companies for which conflicts cannot be adequately mitigated. For FY26, the identities of the peer review contractor and the programmatic review contractor may be found on the CDMRP website.
- Personnel from applicant or collaborating organizations are found to have contacted persons involved in the review or approval process to gain protected evaluation information or to influence the evaluation process.
- The application from an extramural organization, including non-DOW federal agencies, is received through eBRAP.
- The federal government recipient organization (including an intramural DOW organization): (a) cannot accept and execute the entirety of the requested budget in FY26 funds; and/or (b) cannot coordinate the use of contractual, assistance or other appropriate agreements to provide funds to collaborators.

- The application fails to conform to this program announcement description.
- The application includes URLs, with the exception of links in the References Cited and Publication and/or Patent sections.
- The application includes research data that are classified and/or proposes research that may produce classified outcomes, or outcomes deemed sensitive to national security concerns.
- The same research project is submitted to different funding opportunities within the same program and funding cycle.
- The invited application proposes a different consortium effort than that described in the pre-application.
- The application does not address at least one of the FY26 BCRP overarching challenges and did not provide adequate justification for an exception.
- The PI does not meet the eligibility criteria.
- The investigator named as Consortium Director is named as the PI on a pre-application or full application submitted under funding opportunity HT942526BCRPTBCCDA.
- More than one pre-application is received in which the same investigator is named as the Consortium Director. Only the first pre-application received will be accepted; additional applications will be administratively rejected.
- The application fails to name at least one breast cancer consumer advocate per project team, as required by this program announcement.
- Failure to submit all associated (Consortium Director and each Project Team PI) applications by the deadline.

9.2.4. Withhold

Applications that appear to involve research misconduct will be administratively withheld from further consideration pending organizational investigation. The organization will be required to provide the findings of the investigation to the DHACA Grants Officer for a determination of the final disposition of the application.

Appendix 1. Full Application Submission Checklist

Full Application Components	Uploaded	
	Consortium Director	Project Team PIs
SF424 Research & Related Application for Federal Assistance ***(Grants.gov submissions only)***	☐	☐
Summary (Tab 1) and Application Contacts (Tab 2) ***(eBRAP submissions only)***	☐	☐
Attachments		
Project Narrative – Attachment 1, upload as "ProjectNarrative.pdf"	☐	
Supporting Documentation – Attachment 2, upload as "Support.pdf"	☐	
Technical Abstract – Attachment 3, upload as "TechAbs.pdf"	☐	
Lay Abstract – Attachment 4, upload as "LayAbs.pdf"	☐	
Statement of Work – Attachment 5, upload as "SOW.pdf"	☐	☐
Impact Statement – Attachment 6, upload as "Impact.pdf"	☐	
Innovation Statement – Attachment 7, upload as "Innovation.pdf"	☐	
Consortium Plan – Attachment 8, upload as "ConsortiumPlan.pdf"	☐	
Consumer Advocate Statement – Attachment 9, upload as "ConsumerAdvocate.pdf"	☐	
Research Sharing Plan – Attachment 10, upload as "Sharing.pdf"	☐	
Post-Award Transition Plan – Attachment 11, upload as "Transition.pdf"	☐	
Inclusion of Women and Minorities – Attachment 12, upload as "Inclusion.pdf"	☐	
Representations ***(Grants.gov submissions only)*** **– Attachment 13, upload as "RequiredReps.pdf"**	☐	☐
Suggested Intragovernmental/Intramural Budget Form ***(if applicable)*** **– Attachment 14, upload as "IGBudget.pdf"**	☐	☐
Additional Application Materials		
Research & Related Senior/Key Person Profile (Expanded)	☐	☐
Attach Biographical Sketch for Senior/Key Persons (Biosketch_LastName.pdf)	☐	☐
Attach Current/Pending Support for Senior/Key Persons (Support_LastName.pdf)	☐	☐

Research & Related Budget **Include Budget Justification**	☐	☐
Project/Performance Site Location(s)	☐	☐
Research & Related Subaward Budget Attachment(s) ***(if applicable)***	☐	☐

Appendix 2. Acronym List

ARRIVE	Animal Research: Reporting of In Vivo Experiments
BCRP	Breast Cancer Research Program
CDMRP	Congressionally Directed Medical Research Programs
CFR	Code of Federal Regulations
CONSORT	Consolidated Standards of Reporting Trials
DHA	Defense Health Agency
DHA R&D	Defense Health Agency Research and Development
DHACA	Defense Health Agency Contracting Activity
DOD	U.S. Department of Defense
DoDGARs	Department of Defense Grant and Agreement Regulations
DOW	Department of War
eBRAP	Electronic Biomedical Research Application Portal
EC	Ethics Committee
ET	Eastern Time
FAD	Funding Authorization Document
FY	Fiscal Year
GAI	General Application Instructions
GMP	Good Manufacturing Practice
IACUC	Institutional Animal Care and Use Committee
IDE	Investigational Device Exemption
IND	Investigational New Drug
IPR	In-Progress Review
IRB	Institutional Review Board
M	Million
MIPR	Military Interdepartmental Purchase Request
NCI	National Cancer Institute
NIH	National Institutes of Health
ORRC	Office of Research and Regulatory Compliance
PDF	Portable Document Format
PHS	Public Health Service
PI	Principal Investigator
R&D	Research and Development
RPPR	Research Performance Progress Report
SABV	Sex as a Biological Variable

SAM	System for Award Management
SF424 R&R	Standard Form 424 (Application for Federal Assistance, Research & Related)
SOW	Statement of Work
SPIRIT	Standard Protocol Items: Recommendations for Interventional Trials
SPORE	Specialized Programs of Research Excellence
STROBE	STrengthening the Reporting of OBservational studies in Epidemiology
TBCCA	Transformative Breast Cancer Consortium Award
TBCCDA	Transformative Breast Cancer Consortium Development Award
UEI	Unique Entity Identifier
URL	Uniform Resource Locator
USC	United States Code
VA	U.S. Department of Veterans Affairs